(redirected from ABthrax)


(rax-ee-bak-ue-mab) ,


(trade name)


Therapeutic: antidotes
Pharmacologic: temporary class
Pregnancy Category: B


Treatment of inhalational anthrax in combination with anti-infective agents.Prevention of inhalational anthrax when other agents cannot be used or are unavailable.


A monoclonal anti-toxin, blocks the activity of toxin produced by Bacillus anthracisThe toxin is a primary cause of disease progression.

Therapeutic effects

Decreased morbidity and mortality associated with inhalational anthrax exposure and disease.


Absorption: IV administration results in complete bioavailability
Distribution: Some tissue distribution
Metabolism and Excretion: No renal clearance

Time/action profile (levels)

IVrapidend of infusionunknown


Contraindicated in: No contraindications noted.
Use Cautiously in: Infusion reactions (premedication with diphenhyramine is recommended) Obstetric: Effects in pregnant women are not know Lactation: Use cautiously Pediatric: Safe and effective use in children >16 yr has not been studied

Adverse Reactions/Side Effects

Central nervous system

  • drowsiness


  • pruritus
  • rash


  • extremity pain


  • infusion reactions (rash/urticaria/pruritus)


Drug-Drug interaction

None noted.


Pretreatment with diphenhydramine is recommended.
Intravenous (Adults and Children > 50 kg) 40 mg/kg single dose
Intravenous (Children >15 kg-50 kg) 60 mg/kg single dose
Intravenous (Children ≤15 kg) 80 mg/kg single dose


Solution for IV infusion (requires further dilution): 1700 mg/34 mL (50 mg/mL) vial

Nursing implications

Nursing assessment

  • Monitor for infusion-related reactions (rash, urticaria, pruritus). Slow or interrupt infusion if these occur.

Potential Nursing Diagnoses

Risk for infection (Indications)
Deficient knowledge, related to disease process and medication regimen (Patient/Family Teaching)


  • Premedicate within 1 hr of infusion with 25 to 50 mg PO or IV depending on proximity of raxibacumab infusion.
  • Intermittent Infusion: Diluent: Dilute in 0.9% NaCl or 0.45% NaCl for patients up to 15 kg and 0.9% NaCl for patients >15 kg to a final volume of 250 mL or to a volume based on child's weight for either syringe or infusion bag preparation. For syringe preparation, use volume of 7 mL for patients ≤1 kg, 15 mL for patients 1.1–2 kg, 20 mL for patients 2.1–3 kg, 25 mL for patients 3.1–4.9 kg, 50 kg for patients 5–10 kg. Gently mix solution; do not shake. For infusion bag preparation, use volume of 100 mL for patients 16–30 kg, 250 mL for patients 31–40 kg, 250 mL for patients 41 to 50 kg or greater. Gently invert infusion bag; do not shake. Solution is clear to opalescent, colorless to pale yellow; do not administer solutions that are discolored or contain particulate matter. Stable for 8 hr at room temperature.
  • Rate: Infuse over up to 2 hr and 15 min based on patient weight. For patients ≤1 kg, first 20 min infuse at 0.5 mL/hr and remaining infusion over 3.5 mL/hr, patients 1.1–2 kg, first 20 min infuse at 1 mL/hr and remaining infusion over 7 mL/hr, patients 2.1–3 kg, first 20 min infuse at 1.2 mL/hr and remaining infusion over 10 mL/hr, patients 3.1–4.9 kg, first 20 min infuse at 1.5 mL/hr and remaining infusion over 12 mL/hr, patients 5–10 kg, first 20 min infuse at 3 mL/hr and remaining infusion over 25 mL/hr, patients 11–30 kg, first 20 min infuse at 6 mL/hr and remaining infusion over 50 mL/hr, patients 31–50 kg or more, first 20 min infuse at 15 mL/hr and remaining infusion over 125 mL/hr. Rate may be slowed or discontinued if symptoms of adverse reactions or infusion-related reactions occur.

Patient/Family Teaching

  • Explain purpose of raxibacumab to patient or parents.
  • Advise patient to notify health care professional immediately if rash, hives, or itching occur during infusion.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decreased morbidity and mortality associated with inhalational anthrax exposure and disease.
References in periodicals archive ?
The third was ABthrax (raxibacumab), a monoclonal antibody intended to provide passive immunity against anthrax toxin, a product HGS had already begun to produce for the U.
HGS) has received a second order from the federal government for ABthrax, a drug to fight anthrax infection.
The company recently completed delivery of 20,000 doses of the drug, also known as Abthrax, to the health agency as part of a $165 million contract announced in 2006.
HGS began delivery of Abthrax to the Strategic National Stockpile earlier this year.
In January 2009, HGS began delivery of 20,000 doses of ABthrax (raxibacumab) to the United States Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax.
Several pipeline proteins are showing great potential, including: rhGAD65 (Diamyd); DiaPep277; Otelixizumab; Oral-Lyn; NecLip-pdFVIII; OBI-1; NN7008; Long Acting rFactor VIII; Human-cl rhFVIII; Abthrax (raxibacumab) and Simponi (golimumab).
ABthrax (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the United States Government in June 2006.
095 billion for 43 million doses of the currently approved anthrax vaccine (Emergent BioSolutions); $165 million for 20,000 doses of ABthrax, a treatment for anthrax (Human Genome Sciences); $144 million for 10,000 doses of Anthrax Immune Globulin, a treatment for anthrax (Cangene); $363 million for 200,000 doses of botulinum antitoxin, a treatment for botulinum toxin exposure (Cangene); $16 million for 5 million doses of a pediatric form of potassium iodide, a treatment for radioactive iodine exposure (Fleming & Company); $22 million for 395,000 doses of Ca-DTPA and 80,000 doses of Zn-DTPA, two treatments for internal radioactive particle contamination (Akorn); and $500 million for 20 million doses of a new smallpox vaccine (Bavarian Nordic).
In June 2006, HGS announced that the United States government exercised its option under an existing contract to purchase 20,000 doses of ABthrax for the treatment of anthrax disease.
HGS, Human Genome Sciences, ABthrax, Albuferon, BENLYSTA, and ZALBIN are trademarks of Human Genome Sciences, Inc.
Contents Overview of Project BioShield Project BioShield Procurement Process DHS Roles HHS Roles Presidential Roles Interagency Roles Appropriations, Rescissions, and Future Funding Options Appropriations Rescissions Future Funding Options Acquisitions Anthrax rPA Vaccine AVA Vaccine Abthrax Anthrax Immune Globulin Botulinum Toxin Radiological and Nuclear Agents Potassium Iodide Chelators Differences in HHS Contract Awards and Annual Budget Document Accounting Remaining Available Funds Concluding Observations List of Figures Figure 1.